Panacea Biotec sells its domestic formulations business to Mankind Pharma

The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year

Strong show in domestic formulations business by Indian pharma in Q1FY22: Ind-Ra

Domestic business was up 41.9% YoY and 27.7% QoQ

ANG Lifesciences acquires Ind-Swift formulation facilities for Rs 60 cr

The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization

Bal Pharma launches BALflu, Favipiravir formulation in India

BALflu is approved by DCGI for emergency use for the treatment of COVID-19

Biocon partners with Libbs to launch generic formulations in Brazil

Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market

Granules India Q1 FY26 PAT slips to Rs. 112.6 Cr

Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr

The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY

Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr

Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore

Akums reports Q1 FY26 PAT at Rs. 65 Cr

During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals

ZIM Laboratories granted marketing authorization for Tamsulosin + Dutasteride capsules in Australia

Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men